National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®) which is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.


Rapid Review

Commenced Completed Outcome
05/12/2012 04/01/2013  Full Pharmacoeconomic Assessment Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/07/2014*  26/09/2014 Reimbursement Not Recommended

*Formal assessment commenced following legislative changes.

The NCPE does not recommend reimbursement of Sativex® at the submitted price.



NCPE Assessment Process Complete
Rapid review commissioned 12/02/2018
Rapid review completed 03/04/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex® compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 20/04/2018
Pre-submission consultation with Applicant 25/09/2018
Current status Awaiting submission from Applicant

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.